{"analyses":[{"ciLowerLimit":"0.226","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"3.620","estimateComment":"HR is based on an unstratified Cox proportional hazard regression model with treatment as a factor. HR\\<1for the treatment indicates a longer time to Subsequent Therapy in the Pevonedistat Combination arm compared to the Azacitidine only arm.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.888","pValueComment":"P-value is from an unstratified log-rank test.","paramType":"Hazard Ratio (HR)","paramValue":"0.905","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"The median and 95% CI was not estimable due to low number of participants with the event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median and 95% CI was not estimable due to lower number of participants with the event.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"58"}],"units":"Participants"}],"description":"Time to subsequent therapy is defined as time from randomization to the date of the first subsequent therapy. Subsequent therapy is defined as agent(s) with antileukemic/anti-MDS activity. Participants who discontinue study treatment to receive single-agent azacitidine off study did not be counted as receiving subsequent therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG000","title":"Azacitidine 75 mg/m^2"},{"description":"Azacitidine 75 mg/m\\^2, infusion, intravenously or subcutaneously, on Day 1 through Day 5, Days 8 and 9 and pevonedistat 20 mg/m\\^2, infusion, intravenously, on Days 1, 3, and 5 in 28-day treatment cycles until unacceptable toxicity, relapse, transformation to AML (for participants with HR MDS or CMML), or progressive disease (for participants with low-blast AML).","id":"OG001","title":"Azacitidine 75 mg/m^2 + Pevonedistat 20 mg/m^2"}],"paramType":"MEDIAN","populationDescription":"ITT Population was defined as all participants who were randomized.","reportingStatus":"POSTED","timeFrame":"From date of randomization up to approximately 5 years","title":"Time to Subsequent Therapy","type":"SECONDARY","unitOfMeasure":"months"}